OA10114A - New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a : cholesterol acyl transferase (acat) - Google Patents
New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a : cholesterol acyl transferase (acat) Download PDFInfo
- Publication number
- OA10114A OA10114A OA60588A OA60588A OA10114A OA 10114 A OA10114 A OA 10114A OA 60588 A OA60588 A OA 60588A OA 60588 A OA60588 A OA 60588A OA 10114 A OA10114 A OA 10114A
- Authority
- OA
- OAPI
- Prior art keywords
- urea
- bis
- methylpyridin
- methylthio
- heptyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/58—Two sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89005092A | 1992-05-28 | 1992-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA10114A true OA10114A (en) | 1996-12-18 |
Family
ID=25396173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA60588A OA10114A (en) | 1992-05-28 | 1994-11-28 | New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a : cholesterol acyl transferase (acat) |
Country Status (23)
Country | Link |
---|---|
US (1) | US6001860A (fr) |
EP (1) | EP0642498A1 (fr) |
JP (1) | JPH07503737A (fr) |
KR (1) | KR950701621A (fr) |
CN (1) | CN1080919A (fr) |
AU (1) | AU4028393A (fr) |
BG (1) | BG99188A (fr) |
BR (1) | BR9306421A (fr) |
CA (1) | CA2134359C (fr) |
FI (1) | FI932423A (fr) |
HR (1) | HRP930931A2 (fr) |
HU (1) | HUT64303A (fr) |
IL (1) | IL105756A0 (fr) |
IS (1) | IS4023A (fr) |
MA (1) | MA22896A1 (fr) |
MX (1) | MX9303100A (fr) |
OA (1) | OA10114A (fr) |
PL (1) | PL299082A1 (fr) |
RU (1) | RU94046149A (fr) |
SK (1) | SK142694A3 (fr) |
UY (1) | UY23589A1 (fr) |
WO (1) | WO1993024458A1 (fr) |
YU (1) | YU37193A (fr) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2134359C (fr) * | 1992-05-28 | 1997-07-01 | Ernest S. Hamanaka | Nouveaux derives n-aryliques et n-heteroaryluree utilises comme inhibiteurs de l'acyl-coa : cholesterol acyltransferase |
NZ250916A (en) * | 1993-02-27 | 1995-08-28 | Nihon Nohyaku Co Ltd | N-heteroaryl-n'-phenylureas, their use as acat inhibitors |
IL109568A0 (en) * | 1993-05-19 | 1994-08-26 | Fujisawa Pharmaceutical Co | Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
ES2076865B1 (es) * | 1993-07-05 | 1996-08-01 | Pfizer | Nuevos derivados de n-aril- y n-heteroaril-urea como inhibidores de acil-coenzima a: colesterol acil transferasa (acat). |
NZ264063A (en) * | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
DE4401893A1 (de) * | 1994-01-24 | 1995-07-27 | Bayer Ag | Substituierte Arylharnstoffe |
US6133326A (en) * | 1994-08-31 | 2000-10-17 | Pfizer Inc | Compositions and methods for decreasing sebum production |
EP0784612A1 (fr) * | 1994-10-04 | 1997-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Derives d'uree et leur utilisation comme inhibiteurs de l'acat |
CA2185737A1 (fr) * | 1995-09-18 | 1997-03-19 | Akira Yoshida | Derives d'amide et d'uree |
WO1998007718A1 (fr) | 1996-08-22 | 1998-02-26 | Warner-Lambert Company | Antagonistes du recepteur de bombesine non peptidiques |
US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
JP2001521934A (ja) | 1997-11-03 | 2001-11-13 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症薬としての芳香族ヘテロ環式化合物 |
EP1473292A1 (fr) * | 1997-11-03 | 2004-11-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Composes heterocycliques aromatiques convenant en tant qu'agents anti-inflammatoires |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP2298311B1 (fr) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | Urées de diphényle à substitution omega-carboxyaryle en tant qu'inhibiteurs de la p38 kinase |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
MXPA01008440A (es) | 1999-02-22 | 2002-04-24 | Boehringer Ingelheim Pharma | Derivados heterociclicos policiclos como agentes anti-inflamatorios.. |
EP1165516B1 (fr) | 1999-03-12 | 2004-10-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Urees heterocycliques utiles en tant qu'anti-inflammatoires |
WO2000055152A1 (fr) | 1999-03-12 | 2000-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Composes aromatiques heterocycliques utilises en tant qu'agents anti-inflammatoires |
ATE312823T1 (de) | 1999-07-09 | 2005-12-15 | Boehringer Ingelheim Pharma | Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen |
CA2389360C (fr) | 1999-11-16 | 2008-06-03 | Steffen Breitfelder | Derives d'uree utilises comme agents anti-inflammatoires |
US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
KR20020073574A (ko) | 2000-02-02 | 2002-09-27 | 워너-램버트 캄파니 | 피지선 장애 치료용 콜레스테롤 에스테르 및 왁스에스테르 합성 이중 억제제 |
US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
CA2445003A1 (fr) | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Derives de diaryluree utilisables en tant qu'agents anti-inflammatoires |
CA2448626A1 (fr) | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Composes de carbamate et d'oxamide inhibant la production de cytokine |
AU2002351748B2 (en) * | 2001-12-21 | 2009-07-09 | Novo Nordisk A/S | Amide derivatives as GK activators |
WO2003068228A1 (fr) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Urees aryliques a activite inhibitrice d'angiogenese |
DK1580188T3 (da) | 2002-02-11 | 2012-02-06 | Bayer Healthcare Llc | Forbindelser af arylurea som kinaseinhibitorer |
US7041669B2 (en) | 2002-02-25 | 2006-05-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-benzofused urea compounds useful in treating cytokine mediated diseases |
GB0206876D0 (en) * | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
WO2004002481A1 (fr) * | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Activateurs de la glycokinase |
MXPA05007513A (es) * | 2003-01-14 | 2005-09-21 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
US7375126B2 (en) * | 2003-06-12 | 2008-05-20 | Abbott Laboratories | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
US7015233B2 (en) | 2003-06-12 | 2006-03-21 | Abbott Laboratories | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
ME00294B (fr) | 2003-07-23 | 2011-05-10 | Bayer Pharmaceuticals Corp | Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques |
BRPI0506662B8 (pt) | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
ES2686357T3 (es) | 2004-06-17 | 2018-10-17 | Cytokinetics, Inc. | Compuestos, composiciones y procedimientos |
US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
JP2009500378A (ja) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー/エス | グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素 |
JP2009500377A (ja) * | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー/エス | ジシクロアルキルウレア型グルコキナーゼ活性化剤 |
US7884210B2 (en) * | 2005-07-14 | 2011-02-08 | Novo Nordisk A/S | Ureido-thiazole glucokinase activators |
US7538223B2 (en) * | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
US20070208000A1 (en) * | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
WO2007075377A2 (fr) * | 2005-12-15 | 2007-07-05 | Cytokinetics, Inc. | Entites chimiques, compositions et procedes |
US7825120B2 (en) * | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
US20070161617A1 (en) | 2005-12-15 | 2007-07-12 | Morgan Bradley P | Certain chemical entities, compositions and methods |
US7718657B2 (en) * | 2005-12-16 | 2010-05-18 | Cytokinetics, Inc. | Certain indanyl urea modulators of the cardiac sarcomere |
JP5178526B2 (ja) * | 2005-12-19 | 2013-04-10 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
JP5015496B2 (ja) | 2006-06-01 | 2012-08-29 | ルネサスエレクトロニクス株式会社 | 固体撮像装置、撮像方法および撮像システム |
CA2661898A1 (fr) * | 2006-08-25 | 2008-02-28 | Abbott Laboratories | Derives d'indazole inhibant trpv1, et leur utilisation |
JP2010513557A (ja) * | 2006-12-20 | 2010-04-30 | アボット・ラボラトリーズ | 疼痛治療のためのtrpv1バニロイド受容体アンタゴニストとしてのn−(5,6,7,8−テトラヒドロナフタレン−1−イル)尿素誘導体および関連化合物 |
JP2010515701A (ja) * | 2007-01-09 | 2010-05-13 | ノボ・ノルデイスク・エー/エス | ウレアグルコキナーゼアクチベーター |
JP5226008B2 (ja) | 2007-01-11 | 2013-07-03 | ノボ・ノルデイスク・エー/エス | ウレアグルコキナーゼアクチベーター |
BRPI0818339A2 (pt) * | 2007-10-19 | 2015-04-22 | Abbott Gmbh & Co Kg | Produto de dispersão sólida contendo composto à base de n-aril uréia |
WO2009100176A2 (fr) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase |
EP2323989A4 (fr) * | 2008-03-20 | 2011-06-22 | Abbott Lab | Procédés de préparation d'agents destinés au système nerveux central qui sont des antagonistes des trpv1 |
CN103172543B (zh) * | 2011-12-21 | 2016-02-10 | 中国科学院上海药物研究所 | 一种脲类化合物、制备方法及其用途 |
TWI539385B (zh) | 2015-01-28 | 2016-06-21 | 金佶科技股份有限公司 | 光動能指紋辨識模組 |
MX2020008905A (es) | 2018-06-12 | 2020-12-03 | Vtv Therapeutics Llc | Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas. |
KR20240035395A (ko) | 2021-06-14 | 2024-03-15 | 스코르피온 테라퓨틱스, 인코퍼레이티드 | 암 치료에 사용할 수 있는 요소 유도체 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3426031A (en) * | 1967-01-19 | 1969-02-04 | Dow Chemical Co | 3,5,6 - trichloro - 4 - (3 - (alpha,alpha,alpha,alpha',alpha',alpha'-hexafluoro - 3,5 - xylyl)ureido) picolinic acid and the corresponding amide derivative |
US4623662A (en) * | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
US4751026A (en) * | 1986-03-24 | 1988-06-14 | Warner-Lambert Company | Substituted anilides of oleic, linoleic, or linolenic acid as inhibitors of acyl-coa:cholesterol acyltransferase |
US4722927A (en) * | 1986-04-28 | 1988-02-02 | Warner-Lambert Company | Pyrimidine amides of oleic or linoleic acid, composition containing them and their use as inhibitors of acyl-CoA cholesterol acyltransferase |
EP0252524A3 (fr) * | 1986-07-11 | 1989-04-19 | Warner-Lambert Company | Dérivés d'aryl- et aralkylamide d'acides oméga-(phényloxy substitué)-alcanoiques comme inhibiteurs d'acyl-CoA: cholestérol-acyltransférase et compositions pharmaceutiques les contenant |
US4743605A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Saturated fatty acid amides as inhibitors of acyl-coa:cholesterol acyltransferase |
US4716175A (en) * | 1987-02-24 | 1987-12-29 | Warner-Lambert Company | Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase |
US5015644A (en) * | 1987-06-02 | 1991-05-14 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
IE61716B1 (en) * | 1987-06-02 | 1994-11-30 | Warner Lambert Co | Antihyperlipidemic and antiatherosclerotic urea compounds |
EP0297610B1 (fr) * | 1987-07-02 | 1991-03-13 | Warner-Lambert Company | N-[(phényl 2,6-substitué)urées]-carbamates inhibiteurs de l'acyl-co-enzyme A:cholestérol-acyltransférase |
US4868210A (en) * | 1988-03-30 | 1989-09-19 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic compounds and compositions |
US5116848A (en) * | 1988-03-30 | 1992-05-26 | Warner-Lambert Company | N-(((2,6-disubstituted)phenyl)-n-diarylalkyl)ureas as antihyperlipidemic and antiatherosclerotic agents |
US5155127A (en) * | 1989-02-09 | 1992-10-13 | Warner-Lambert Company | N-(substituted aryl)-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents |
US4994465A (en) * | 1989-02-17 | 1991-02-19 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds |
PT93158A (pt) * | 1989-02-17 | 1990-08-31 | Warner Lambert Co | Processo para a preparacao de compostos de ureia trissubstituidos e de composicoes farmaceuticas que os contem |
AU632809B2 (en) * | 1989-05-25 | 1993-01-14 | Takeda Chemical Industries Ltd. | Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof |
ZA903906B (en) * | 1989-05-25 | 1992-02-26 | Takeda Chemical Industries Ltd | Benzocycloalkane derivatives and production thereof |
CA2022346A1 (fr) * | 1989-08-04 | 1991-02-05 | Mitsubishi Chemical Corporation | Derives de 1-phenylalkyl-3-phenyluree |
WO1991004027A1 (fr) * | 1989-09-15 | 1991-04-04 | Pfizer Inc. | Nouveaux derives de n-aryle de n-heteroarylamide et d'uree en tant qu'inhibiteurs d'acyl coenzyme a: cholesterol acyl transferase |
TW205037B (fr) * | 1989-10-06 | 1993-05-01 | Takeda Pharm Industry Co Ltd | |
JPH05310678A (ja) * | 1990-01-22 | 1993-11-22 | Mitsubishi Kasei Corp | 1−フェニルアルキル−3−フェニル尿素誘導体 |
DE69105786T2 (de) * | 1990-03-12 | 1995-04-27 | Yamanouchi Pharma Co Ltd | Harnstoffderivate, deren Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen. |
WO1991013871A1 (fr) * | 1990-03-12 | 1991-09-19 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de monouree et ses sels |
US5668136A (en) * | 1990-09-25 | 1997-09-16 | Eisai Co., Ltd. | Trisubstituted benzene derivatives, composition and methods of treatment |
FR2674522B1 (fr) * | 1991-03-26 | 1993-07-16 | Lipha | Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant. |
IL101785A0 (en) * | 1991-05-10 | 1992-12-30 | Fujisawa Pharmaceutical Co | Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
CA2134359C (fr) * | 1992-05-28 | 1997-07-01 | Ernest S. Hamanaka | Nouveaux derives n-aryliques et n-heteroaryluree utilises comme inhibiteurs de l'acyl-coa : cholesterol acyltransferase |
-
1993
- 1993-04-20 CA CA002134359A patent/CA2134359C/fr not_active Expired - Fee Related
- 1993-04-20 US US08/343,557 patent/US6001860A/en not_active Expired - Fee Related
- 1993-04-20 RU RU94046149/04A patent/RU94046149A/ru unknown
- 1993-04-20 WO PCT/US1993/003539 patent/WO1993024458A1/fr not_active Application Discontinuation
- 1993-04-20 BR BR9306421A patent/BR9306421A/pt not_active Application Discontinuation
- 1993-04-20 SK SK1426-94A patent/SK142694A3/sk unknown
- 1993-04-20 AU AU40283/93A patent/AU4028393A/en not_active Abandoned
- 1993-04-20 KR KR1019940704262A patent/KR950701621A/ko not_active Application Discontinuation
- 1993-04-20 EP EP93909519A patent/EP0642498A1/fr not_active Withdrawn
- 1993-04-20 JP JP6500522A patent/JPH07503737A/ja active Pending
- 1993-05-20 IL IL105756A patent/IL105756A0/xx unknown
- 1993-05-24 IS IS4023A patent/IS4023A/is unknown
- 1993-05-26 HR HR07/890,050A patent/HRP930931A2/hr not_active Application Discontinuation
- 1993-05-26 MX MX9303100A patent/MX9303100A/es unknown
- 1993-05-26 PL PL93299082A patent/PL299082A1/xx unknown
- 1993-05-27 YU YU37193A patent/YU37193A/sh unknown
- 1993-05-27 MA MA23195A patent/MA22896A1/fr unknown
- 1993-05-27 CN CN93106774A patent/CN1080919A/zh active Pending
- 1993-05-27 HU HU9301552A patent/HUT64303A/hu unknown
- 1993-05-27 FI FI932423A patent/FI932423A/fi not_active Application Discontinuation
- 1993-05-28 UY UY23589A patent/UY23589A1/es unknown
-
1994
- 1994-11-17 BG BG99188A patent/BG99188A/bg unknown
- 1994-11-28 OA OA60588A patent/OA10114A/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU94046149A (ru) | 1996-11-27 |
UY23589A1 (es) | 1993-11-15 |
KR950701621A (ko) | 1995-04-28 |
BR9306421A (pt) | 1998-09-15 |
BG99188A (bg) | 1995-07-28 |
CA2134359A1 (fr) | 1993-12-09 |
WO1993024458A1 (fr) | 1993-12-09 |
CA2134359C (fr) | 1997-07-01 |
MX9303100A (es) | 1994-06-30 |
JPH07503737A (ja) | 1995-04-20 |
FI932423A0 (fi) | 1993-05-27 |
HUT64303A (en) | 1993-12-28 |
HRP930931A2 (en) | 1997-06-30 |
PL299082A1 (en) | 1994-04-05 |
HU9301552D0 (en) | 1993-09-28 |
CN1080919A (zh) | 1994-01-19 |
YU37193A (sh) | 1997-07-31 |
AU4028393A (en) | 1993-12-30 |
FI932423A (fi) | 1993-11-29 |
SK142694A3 (en) | 1995-06-07 |
IS4023A (is) | 1993-11-29 |
EP0642498A1 (fr) | 1995-03-15 |
IL105756A0 (en) | 1993-09-22 |
US6001860A (en) | 1999-12-14 |
MA22896A1 (fr) | 1993-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA10114A (en) | New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a : cholesterol acyl transferase (acat) | |
US5362878A (en) | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) | |
FI111362B (fi) | Menetelmä terapeuttisesti käyttökelpoisten N-heteroaryyliamidijohdannaisten valmistamiseksi | |
US5596001A (en) | 4-aryl-3-(heteroarylureido)quinoline derivatves | |
AU664694B2 (en) | Benzamides | |
US5147876A (en) | 2,6-di,2,4,6-, 2,5,6-tri and 2,4,5,6-tetra-substituted pyrimidines, their pharmaceutically acceptable salts, pharmaceutical compositions containing same and their use in the treatment of neurological diseases | |
EP0235164B1 (fr) | Analogues d'imidazole de mevalonolactone et leurs derives | |
EP3594221B1 (fr) | Antagoniste du récepteur gpr84 et son utilisation | |
KR100239800B1 (ko) | 4,5-디아미노 피리미딘 유도체 및 이의 제조방법 | |
US5565472A (en) | 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents | |
EP0623112B1 (fr) | Dérivés de 4-phenyl-(heteroarylureido)-1,2-dihydro-2-oxoquinoleine utilises comme agents antihypercholesterolemie et antiatherosclerose | |
EP0590094A1 (fr) | Derives de 4-aryle-3-(heteroarylureido)quinoline | |
WO1998006401A1 (fr) | Composes pharmaceutiquement actifs et procedes d'utilisation desdits composes | |
HU202506B (en) | Process for producing benzoxazolone derivatives | |
EP1019376A1 (fr) | Derives de pyridone, leur preparation et leur utilisation comme intermediaires de synthese | |
DK170334B1 (da) | 2-Pyridonderivater og tautomere og syreadditionssalte deraf, fremgangsmåde til fremstilling deraf, farmaceutiske præparater med indhold deraf samt anvendelse af 2-pyridonderivaterne til fremstilling af farmaceutiske præparater | |
Kennedy et al. | Preparation and Nucleic Acid Binding of Ellipticine Derivatives | |
CN101412696A (zh) | 4,5-二芳基吡唑-3-胺基衍生物及其制备和用途 |